39 results
425
MREO
Mereo Biopharma Group Plc
6 Dec 18
Business combination disclosure
2:27pm
monoclonal antibody that targets and inhibits both Delta-like ligand 4 and vascular endothelial growth factor Etigilimab (“anti-TIGIT”): antibody … that targets the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), an inhibitory receptor that is thought to stop T-cells from attacking
425
OncoMed Pharmaceuticals Inc
6 Dec 18
Business combination disclosure
2:27pm
candidates include:
Etigilimab, an antibody that targets the T-cell immunoreceptor with immunoglobulin and ITIM domains (“TIGIT”), an inhibitory receptor … is part ofOncoMed’s collaboration with Celgene;
Navicixizumab (“NAVI”), a bispecific monoclonal antibody that targets and inhibits both Delta-like
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
Exhibit 99.1
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
Targets 40% Reduction in Headcount and Significant
425
MREO
Mereo Biopharma Group Plc
11 Dec 18
Business combination disclosure
1:16pm
) Phase 1a data due in 2019 Phase 1 Phase 1A Phase 1A Navicixizumab (“NAVI”): bispecific monoclonal antibody that targets and inhibits both Delta - like … ligand 4 and vascular endothelial growth factor Etigilimab (“anti - TIGIT”): antibody that targets the T - cell immunoreceptor with immunoglobulin
425
MREO
Mereo Biopharma Group Plc
15 Feb 19
Business combination disclosure
6:50am
Navicixizumab (“NAVI”): bispecific monoclonal antibody that targets and inhibits both Delta - like ligand 4 and vascular endothelial growth factor Etigilimab … (“anti - TIGIT”): antibody that targets the T - cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), an inhibitory receptor
425
efaaf7b7yy81m05q8q6
7 Jan 19
Business combination disclosure
11:50am
425
xfixm4x91do
12 Feb 19
Business combination disclosure
12:00am
6-K
EX-99.1
zv0xvt hrupx4g
16 Nov 23
Current report (foreign)
7:01am
6-K
EX-99.1
h4ojh
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
EX-99.1
u7wh0ydc mi44vsqtm5
16 Apr 21
Current report (foreign)
4:10pm
6-K
EX-99.1
y0sdmg5fxo
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
soiqo83 kgwssv0
14 Jan 21
Current report (foreign)
7:06am
S-8
EX-99.1
oybq02ueokgn7yk54ac
21 May 19
Registration of securities for employees
1:53pm
S-8
EX-99.1
2zf1dan
15 Jan 21
Registration of securities for employees
4:21pm
S-8
EX-99.1
arh ref4fgretjxkk
18 Feb 20
Registration of securities for employees
5:17pm
20-F
EX-4.7
pe4jb
29 Apr 19
Annual report (foreign)
4:59pm
F-4
EX-10.3
6t0vispazu0vtxw4ar
25 Jan 19
Registration of securities (foreign)
12:00am
F-4
EX-10.4
ui8 pfbfnp
25 Jan 19
Registration of securities (foreign)
12:00am
F-4
EX-10.5
bwkjs
25 Jan 19
Registration of securities (foreign)
12:00am